NCT05104723View on ClinicalTrials.gov

Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 12, 2022

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Chronic Granulomatous DiseaseInflammatory Gastrointestinal DiseaseInflammatory Skin DiseaseInflammatory Lung Disease
Interventions
DRUG

XELJANZ (tofacitinib)

The XELJANZ 5-mg tablets or 11-mg XR tablets will taken orally twice daily or once daily, respectively, in this study.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH